S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:NEXI

NexImmune (NEXI) Stock Price, News & Analysis

$5.61
+0.10 (+1.81%)
(As of 03/28/2024 ET)
Today's Range
$5.51
$5.70
50-Day Range
$5.00
$15.19
52-Week Range
$1.25
$28.69
Volume
12,192 shs
Average Volume
2.26 million shs
Market Capitalization
$5.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NEXI stock logo

About NexImmune Stock (NASDAQ:NEXI)

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NEXI Stock Price History

NEXI Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
NexImmune slips after securities offering
NexImmune, Inc. Common Stock (NEXI)
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Why Is NexImmune (NEXI) Stock Up 353% Today?
NexImmune Inc Ordinary Shares NEXI
NexImmune Announces 1-for-25 Reverse Stock Split
NexImmune announces 53% reduction in workforce
See More Headlines
Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NEXI
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

Net Income
$-62,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$33.43 per share

Miscellaneous

Free Float
853,000
Market Cap
$5.94 million
Optionable
Not Optionable
Beta
1.90
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Ms. Kristi Jones R.Ph. (Age 61)
    CEO, President & Director
    Comp: $680.44k
  • Dr. Mathias Oelke Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $621.26k
  • Mr. John Trainer M.B.A. (Age 50)
    Consultant
    Comp: $546.13k
  • Dr. Jerome Bernard Zeldis M.D. (Age 74)
    Ph.D., Consultant
    Comp: $618.2k
  • Mr. Timothy Stover
    VP, Corporate Controller and Principal Financial & Accounting Officer
  • Mr. Karen Haslbeck
    Head of Human Resources
  • Dr. Daniel P. Bednarik
    Senior Vice President of Molecular Engineering & Protein Design
  • Dr. Robert Douglas Knight M.D. (Age 73)
    Chief Medical Officer
    Comp: $454.77k
  • Mr. Chad Rubin
    Senior Vice President of Corporate Affairs
  • Dr. Jack A. Ragheb M.D.
    Ph.D., Senior Vice President of Translational Science

NEXI Stock Analysis - Frequently Asked Questions

How have NEXI shares performed in 2024?

NexImmune's stock was trading at $2.22 at the start of the year. Since then, NEXI shares have increased by 152.7% and is now trading at $5.61.
View the best growth stocks for 2024 here
.

Are investors shorting NexImmune?

NexImmune saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 35,200 shares, an increase of 122.8% from the February 29th total of 15,800 shares. Based on an average daily trading volume, of 2,120,000 shares, the short-interest ratio is currently 0.0 days. Approximately 4.5% of the shares of the company are sold short.
View NexImmune's Short Interest
.

How were NexImmune's earnings last quarter?

NexImmune, Inc. (NASDAQ:NEXI) issued its quarterly earnings data on Friday, November, 12th. The company reported ($16.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($16.75) by $0.50.

When did NexImmune's stock split?

NexImmune's stock reverse split before market open on Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did NexImmune IPO?

NexImmune (NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO.

Who are NexImmune's major shareholders?

NexImmune's stock is owned by a number of institutional and retail investors. Top institutional shareholders include PNC Financial Services Group Inc. (1.19%) and PNC Financial Services Group Inc. (1.19%). Insiders that own company stock include Alan S Roemer, Grant Verstandig, Kristi Jones and Sol J Barer.
View institutional ownership trends
.

How do I buy shares of NexImmune?

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NEXI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners